As cited by the research report titled ‘U.S. Non-Invasive Prenatal Testing Market Research and Outlook, 2021 - Trends, Growth Opportunities, Competitive Analysis and Forecasts to 2028’, available with MarketStudyReport, United States non-invasive prenatal testing market is estimated to reach a valuation of USD 2.5 billion over 2021-2028.
 

Rising per capita income, growing incidences of chromosomal aneuploidies, and introduction of advanced products are major factors driving the growth of United States non-invasive prenatal testing market.
 

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/3950419/
 

Increasing awareness regarding the benefits of these testing methods, augmenting focus on reimbursements, and rising preference towards using non-invasive techniques as compared to invasive methods are also adding traction to the overall market size.
 

Introduction of ACOG guidelines that recommend going through NIPT for all pregnancies irrespective of risk is positively swaying the business dynamics in the United States. 
 

The research literature entails a detailed assessment of the past and present trends of the industry and estimation of the market size over the analysis timeframe. It also identifies the major restraints and limitations, and provides relevant solutions for the same.
 

A comprehensive assessment of the market segmentation and regional landscape is included in the document to provide a clear perspective of this business sphere. All the segments are individually studied with respect to production type, consumption patterns, and growth rate, further allowing to identify the major growth avenues for stakeholders to boost their profitability graph.
 

The market report incorporates in-depth analysis of competitive terrain by focusing on the performance of the major participants in the industry. Speaking of which, the major players swaying the United States non-invasive prenatal testing industry trends are Agilent Technologies Inc., PerkinElmer Inc., Progenity Inc., GenPath Diagnostics, Invitae Corporation, Centogene N.V., Myriad Genetics Inc., Quest Diagnostics, Natera Inc., Illumina Inc., Ariosa Diagnostics (Roche), Yourgene Health, and Integrated Genetics (LabCorp).
 

The competitive landscape section also includes a data on latest agreements, mergers & acquisitions, collaborations, and partnerships. By explaining the aspects, the report recommends various strategies to assist stakeholders in reducing their costs, developing contingency plans, and subsequently amassing lucrative returns.